Radiotherapy combined with immunomodulator therapy for monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) after surgery and chemotherapy: a case report

Monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) is a mature T‐cell lymphoma that originates from intestinal intraepithelial T lymphocytes. It is a rare malignancy with a poor prognosis and a median overall survival of only 7 months. Currently, there is no standard treatment regimen for MEITL, and chemotherapy is the most commonly used approach. However, the application of radiotherapy and immunomodulators has rarely been reported. This report describes a case of MEITL in a middle‐aged male. The patient initially received CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) chemotherapy but failed to complete the planned course owing to Grade IV leukopenia. Subsequently, the patient underwent whole abdominal radiotherapy (WART). After the completion of WART, the patient was continuously administered lenalidomide‐dexamethasone (LenDex). Excellent therapeutic efficacy was achieved, with no evidence of disease confirmed by regular post‐treatment follow‐up and disease‐free survival exceeding 24 months. The combination of WART and LenDex for MEITL has not been previously reported and its potential therapeutic value may provide valuable insights for clinical practice and future research.

Authors

Institutions

Publication Details

Journal
Precision Radiation Oncology
Published
2026-11-18
DOI
https://doi.org/10.1002/pro6.70091
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Radiotherapy combined with immunomodulator therapy for monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) after surgery and chemotherapy: a case report

Yongchang Wei, Min Luo, Liang Wei
4 links
Precision Radiation Oncology
Lymphoma Diagnosis and Treatment
article

Radiotherapy combined with immunomodulator therapy for monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) after surgery and chemotherapy: a case report

Yongchang Wei, Min Luo, Liang Wei
article en

Abstract

Monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) is a mature T‐cell lymphoma that originates from intestinal intraepithelial T lymphocytes. It is a rare malignancy with a poor prognosis and a median overall survival of only 7 months. Currently, there is no standard treatment regimen for MEITL, and chemotherapy is the most commonly used approach. However, the application of radiotherapy and immunomodulators has rarely been reported. This report describes a case of MEITL in a middle‐aged male. The patient initially received CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) chemotherapy but failed to complete the planned course owing to Grade IV leukopenia. Subsequently, the patient underwent whole abdominal radiotherapy (WART). After the completion of WART, the patient was continuously administered lenalidomide‐dexamethasone (LenDex). Excellent therapeutic efficacy was achieved, with no evidence of disease confirmed by regular post‐treatment follow‐up and disease‐free survival exceeding 24 months. The combination of WART and LenDex for MEITL has not been previously reported and its potential therapeutic value may provide valuable insights for clinical practice and future research.

Precision Radiation Oncology
Wuhan University (CN), Zhongnan Hospital of Wuhan University (CN)
Good health and well-being
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon